Article Contents ::
- 1 The Brand Name DIALONG Has Generic Salt :: Glibenclamide
- 2 DIALONG Is From Company Armour Rem. Priced :: Rs. 5
- 3 DIALONG have Glibenclamide is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name DIALONG Has Generic Salt :: Glibenclamide
DIALONG Is From Company Armour Rem. Priced :: Rs. 5
DIALONG have Glibenclamide is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Type 2 DM
Drug Dose ::
Adult: PO Initial: 2.5-5 mg/day, up to 15 mg/day. Max: 20 mg/day.
Severe or life-threatening hyperglycaemia, severe liver or renal failure, type 1 diabetes, diabetic ketoacidosis with or without coma, patients with severe infection or trauma.
Drug Precautions ::
Elderly; malnourished; mild to moderate renal and hepatic disorders. Impaired alertness. Avoid alcohol. Careful monitoring of blood-glucose concentration. Adrenocortical insufficiency. Changes in diet or prolonged exercise may also provoke hypoglycaemia. Increased risk of hypoglcaemia due to its long half-life. Avoid in severe hepatic impairment. Pregnancy, lactation.
Drug Side Effects ::
Hypoglycaemia; cholestatic jaundice; agranulocytosis; aplastic anaemia; haemolytic anaemia. Blood dyscrasias (reversible), liver dysfunction, hypoglycaemia, GI symptoms, allergic skin reactions. Potentially Fatal: Prolonged hypoglycaemia seen in elderly or debilitated patients with hepatic or renal diseases.
Pregnancy category ::
Drug Mode of Action ::
Glibenclamide lowers blood glucose concentration principally by stimulating secretion of endogenous insulin from the pancreatic ?-cells. Hypoglycaemic action associated w/ short-term therapy appears to include reduction of basal hepatic glucose production and enhancement of peripheral insulin action at target sites.
Drug Interactions ::
Serum levels may be reduced by colesevelam. May increase hypoglycaemic effect w/ MAOIs, chloramphenicol, fluoroquinolones (e.g. ciprofloxacin), probenecid, NSAIDs, ACE inhibitors, fluoxetine, disopyramide, clarithromycin, salicylates, sulfonamides, ?-blockers. Increased serum levels w/ antifungal antibiotics (e.g. miconazole, fluconazole). May decrease hypoglycaemic effect w/ nonthiazide (e.g. furosemide) and thiazide diuretics, corticosteroids, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetic agents, rifampicin, Ca channel blockers, isoniazid. Potentially Fatal: May increase hepatotoxic effect of bosentan.